Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Global Blood Therapeutics, Inc. - Common Stock (NQ: GBT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
50 Biggest Movers From Yesterday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 143.8% to settle at $12.19 on Tuesday after the company priced its IPO at $5 per share, MIND Technology, Inc. (NASDAQ: MIND... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q3 sales of $52.05 million. Earnings fell to a loss of $70.99 million, resulting in a 2.01% decrease from last... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Global Blood Therapeutics (GBT) Q3 2021 Earnings Call Transcript
GBT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
See Why Jefferies Sees Massive Upside In Global Blood Therapeutics
Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers TransCode Therapeutics (NASDAQ:RNAZ 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Global Blood's Sickle Cell Medicine Under FDA Review For Expanded Use
The FDA has accepted Global Blood Therapeutics Inc's (GBT) (NASDAQ: GBT) supplemental application seeking accelerated approval for Oxbryta (voxelotor) for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Why Shares of Global Blood Therapeutics Are Soaring Today
The biotech company has only one drug, Oxbryta, on the market, to treat sickle cell disease. Its shares were up Monday after falling on Friday. 
Via The Motley Fool
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
88 Biggest Movers From Yesterday
Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
Via Benzinga
Why Global Blood Therapeutics Is Rallying Today
This heavily shorted biotech finally had some good news. 
Via The Motley Fool
Global Blood Shoots 17% Higher As Q2 Earnings Beat Estimates; Analyst Upgrades Stock
Global Blood Therapeutics Inc (NASDAQ: GBT) reported Q2 Oxbryta (voxelotor) sales of $47.55 million, +51% Y/Y, beating the consensus of $43.84 million. On a sequential... 
Via Benzinga
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2021
Upgrades For Meritage Homes Corp (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers BeyondSpring (NASDAQ:BYSI) stock increased by 337.79% to $42.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6... 
Via Benzinga
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers Alterity Therapeutics Limited (NASDAQ: ATHE) shares rose 34.8% to $1.84 in pre-market trading after gaining around 3% on Tuesday. Wheeler Real Estate Investment Trust,... 
Via Benzinga
Global Blood Therapeutics (GBT) Q2 2021 Earnings Call Transcript
GBT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Global Blood Submits US Application For Expanded Use Of SCD Drug, Oxbryta, In Patients Aged 4-11 Years
Global Blood Therapeutics Inc (NASDAQ: GBT) has submitted a supplemental marketing application to the FDA seeking accelerated approval for Oxbryta (voxelotor) for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday morning, 69 companies achieved new lows for the year. Intriguing Points: Las Vegas Sands (NYSE:LVS) was the largest firm by market cap to set a new 52-... 
Via Benzinga
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.